ZVRA logo

Zevra Therapeutics Inc. (ZVRA)

$9.40

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on ZVRA

Market cap

$559343437

EPS

1.21

P/E ratio

12.1

Price to sales

4.97

Dividend yield

--

Beta

1.01622

Price on ZVRA

Previous close

$9.25

Today's open

$9.24

Day's range

$9.04 - $9.41

52 week range

$8.01 - $15.04

Profile about ZVRA

CEO

Neil F. Mcfarlane

Employees

61

Headquarters

Boston, MA

Exchange

Nasdaq Global Select

Shares outstanding

59504621

Issue type

Common Stock

ZVRA industries and sectors

Healthcare

Biotechnology & Life Sciences

News on ZVRA

Zevra Therapeutics to Present at the Piper Sandler Annual Healthcare Conference

BOSTON, Nov. 18, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company committed to redefining what's possible in bringing life-changing therapeutics to people living with rare diseases, today announced that members of Zevra's executive leadership team will present at the Piper Sandler 38th Annual Healthcare Conference in New York, NY on Wednesday, December 2, 2026, at 1:00 p.m. ET.

news source

GlobeNewsWire • 11 hours ago

news preview

Zevra Therapeutics Announces Final CHMP Opinion on Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European Union

European Commission to make final decision on arimoclomol MAA following negative CHMP opinion European Commission to make final decision on arimoclomol MAA following negative CHMP opinion

news source

GlobeNewsWire • Nov 13, 2026

news preview

Wall Street Analysts Believe Zevra Therapeutics (ZVRA) Could Rally 117.86%: Here's is How to Trade

The mean of analysts' price targets for Zevra Therapeutics (ZVRA) points to an 117.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

news source

Zacks Investment Research • Nov 9, 2026

news preview

Zevra Therapeutics Q3 Earnings Call Highlights

Zevra Therapeutics NASDAQ: ZVRA reported third-quarter 2026 net revenue of $37.8 million, up 45% from $26.1 million a year earlier, driven primarily by U.S. sales of MIPLYFFA for Niemann-Pick disease type C, or NPC.

news source

MarketBeat • Nov 3, 2026

news preview

Zevra Therapeutics, Inc. (ZVRA) Q3 2026 Earnings Call Transcript

Zevra Therapeutics, Inc. (ZVRA) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 4, 2026

news preview

Zevra Reports Third Quarter 2026 Financial Results and Corporate Update

$37.8 million net revenue for Q3 2026 , driven by $34.0 million in revenue from MIPLYFFA

news source

GlobeNewsWire • Nov 3, 2026

news preview

Zevra Therapeutics (ZVRA) Q3 Earnings and Revenues Beat Estimates

Zevra Therapeutics (ZVRA) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to a loss of $0.01 per share a year ago.

news source

Zacks Investment Research • Nov 3, 2026

news preview

Zevra Therapeutics Announces Details for Q3 2026 Financial Results Call

BOSTON, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced it will report corporate and financial results for the third quarter on Tuesday, November 3, 2026, via a news release after the market close, and will host a conference call/audio webcast at 4:30 p.m. ET that day.

news source

GlobeNewsWire • Oct 20, 2026

news preview

Zevra Therapeutics: Cash Plus A Drug Priced Below Its Rival's Deal

Zevra Therapeutics is rated Buy, with a fair value of $13.38 per share, 28.7% above current levels. ZVRA's valuation is anchored by $260.2M in cash and a drug business priced at less than a fifth of its rival's acquisition value. Miplyffa's US launch is slow but stable; key risks are insurer restrictions and potential sales declines, with Europe currently valued at zero.

news source

Seeking Alpha • Oct 15, 2026

news preview

Zevra Therapeutics: Miplyffa Validates The Bull Case, Europe Still The Swing Factor

Zevra Therapeutics is a buy-rated, single-asset rare disease play with Miplyffa driving strong U.S. growth and early profitability. 2Q26 net revenue reached $39.7M, up 53% YoY, with Miplyffa contributing $30.2M and high patient retention supporting a durable franchise thesis. Management's diagnosis expansion efforts suggest the NPC addressable market may be up to 900 patients, extending the growth runway beyond initial estimates.

news source

Seeking Alpha • Oct 6, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Zevra Therapeutics Inc.

Open an M1 investment account to buy and sell Zevra Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in ZVRA on M1